DOVER, Del. and SHANGHAI, June 1, 2018 /PRNewswire/ -- Xynomic Pharma, a clinical stage US-China oncology drug development company, today announced that it has completed Series B Crossover financing, led by experienced healthcare investors Northern Light Venture Capital, Zhongshan Bison Healthcare Investment Limited and Hakim Unique Internet Company Limited. All existing investors including Prosperico Ventures and Mr. Yinglin Mark Xu, Xynomic Pharma's founder and Chairman, participated in this round of financing.
The Series B proceeds will be used to initiate eight clinical trials, four of which are pivotal, in the next 12 months:
About Xynomic Pharmaceuticals, Inc.Xynomic Pharmaceuticals, Inc. is a clinical stage oncology-focused biopharmaceutical company. Its lead drug candidate Abexinostat has already been tested on approximately 600 patients worldwide in 18 clinical trials, showing a more favorable safety profile among HDAC products and significant clinical benefits in patients with RCC and non-Hodgkin's lymphoma. Xynomic's pipeline also includes XP-102 (BI 882370), XP-103 and XP-104.
Media Contact: [email protected]
Business Development Contact: [email protected]
Advertisement
The Series B proceeds will be used to initiate eight clinical trials, four of which are pivotal, in the next 12 months:
- Xynomic's lead drug candidate Abexinostat (Abex) combined with Pazopanib to treat patients with locally advanced or metastatic renal cell carcinoma (global pivotal, fast track designation, protocol already OK'ed by the US FDA);
- Abex as a monotherapy against r/r follicular lymphoma (global pivotal, accelerated approval, protocol already OK'ed by the US FDA);
- Abex as a monotherapy against r/r follicular lymphoma in China (pivotal trial);
- Abex as a monotherapy against r/r diffuse large B-cell lymphoma (DLBCL) in China (pivotal trial);
- Abex combined with Imbruvica against r/r DLBCL and r/r mantel cell lymphoma (Phase 1/2, in partnership with Janssen and Memorial Sloan Kettering Cancer Center);
- Abex combined with Keytruda against multiple solid tumors (Phase 1b, in partnership with University of California, San Francisco);
- Abex combined with a leading breast cancer drug against Estrogen Receptor (ER)+ breast cancer (Phase 1/2);
- Xynomic's XP-102 (a 2nd generation, potentially best-in-class pan-RAF inhibitor) against colorectal cancer and melanoma (Phase 1).
Advertisement
About Xynomic Pharmaceuticals, Inc.Xynomic Pharmaceuticals, Inc. is a clinical stage oncology-focused biopharmaceutical company. Its lead drug candidate Abexinostat has already been tested on approximately 600 patients worldwide in 18 clinical trials, showing a more favorable safety profile among HDAC products and significant clinical benefits in patients with RCC and non-Hodgkin's lymphoma. Xynomic's pipeline also includes XP-102 (BI 882370), XP-103 and XP-104.
Media Contact: [email protected]
Business Development Contact: [email protected]
View original content:http://www.prnewswire.com/news-releases/xynomic-pharma-completes-series-b-crossover-financing-starts-four-pivotal-trials-in-renal-cell-carcinoma-rcc-and-lymphoma-and-opens-a-rd-center-300658004.html
SOURCE Xynomic Pharmaceuticals, Inc.
